BridgeBio Pharma Inc (BBIO) — Tangible Net Worth Ratio

Latest as of December 2020: 100.0%

BridgeBio Pharma Inc (BBIO) has a Tangible Net Worth Ratio of 100.0% as of December 2020. This metric is calculated by deducting intangible assets ($0.00) from net assets ($107.89 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore BridgeBio Pharma Inc (BBIO) equity growth momentum to track the company's year-over-year net asset growth rate.

Tangible NW Ratio

100.0%
Tangible equity / total equity

Net Assets (Equity)

$107.89 Million
USD

Intangible Assets

$0.00
Goodwill, patents, brand value

Total Assets

$703.59 Million
USD

BridgeBio Pharma Inc Tangible Net Worth Ratio (2019–2020)

This chart shows how BridgeBio Pharma Inc's Tangible Net Worth Ratio has changed across 2 annual periods from 2019 to 2020. As of December 2020, the ratio stands at 100.0%, reflecting net assets of $107.89 Million with intangible assets of $0.00 USD. For live market cap and overall valuation, see BridgeBio Pharma Inc market capitalisation.

Annual Tangible Net Worth Ratio for BridgeBio Pharma Inc (2019–2020)

The table below presents the year-by-year Tangible Net Worth Ratio for BridgeBio Pharma Inc from 2019 to 2020, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore BBIO capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.

Year Tangible NW Ratio Net Assets (USD) Intangible Assets Total Assets Change (pp)
2020 100.0% $107.89 Million $0.00 $703.59 Million ▲ +0.0 pp
2019 100.0% $475.98 Million $0.00 $631.68 Million
pp = percentage points